Jasper Therapeutics Inc (JSPRW) Financials
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the JSPRW SEC filings page.
This page shows Jasper Therapeutics Inc (JSPRW) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Jasper's dominant mechanic is a cash-consuming development model becoming more dependent on external financing as equity absorbs losses.
The earnings-to-cash gap is narrow: FY2025 operating loss was-$83.9M versus operating cash flow of-$77.2M , indicating reported losses largely represent current cash spending rather than mainly non-cash charges. Assets nearly halved between FY2024 and FY2025, while debt-to-equity jumped to 7.6x from 0.3x, showing a much thinner equity cushion.
R&D intensity remained central: spending reached
External financing supplied
Financial Health Signals
Jasper Therapeutics Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Jasper Therapeutics Inc passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Jasper Therapeutics Inc reported a net loss of $76 while operations used $77.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Jasper Therapeutics Inc's EBITDA was $11.8M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 144.0% from the same quarter a year earlier. Against the prior quarter it is up 207.9%.
Jasper Therapeutics Inc reported -$2.8M in net income in Q2 2026. This represents an increase of 89.7% from the same quarter a year earlier. Against the prior quarter it is down 135.1%.
Jasper Therapeutics Inc earned -$0.10 per diluted share (EPS) in Q2 2026. Against the prior quarter it is down 150.0%.
Not reported for Q2 2026.
Cash & Balance Sheet
Jasper Therapeutics Inc held $7.3M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Jasper Therapeutics Inc's ROE was -195.3% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 81.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 160.8 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Jasper Therapeutics Inc invested $5.1M in research and development in Q2 2026. This represents a decrease of 75.8% from the same quarter a year earlier. Against the prior quarter it is down 11.7%.
Not reported for Q2 2026.
Not reported for Q2 2026.
JSPRW Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | $3.6M-77.3% | $3.6M-62.9% | N/A | $9.3M+6.4% | $15.8M | $9.8M | N/A | $8.8M |
| R&D Expenses | $5.1M-75.8% | $5.8M-64.0% | N/A | $14.4M-0.4% | $21.2M+87.6% | $16.2M+56.9% | N/A | $14.5M-2.6% |
| SG&A Expenses | $4.1M-30.7% | $5.1M-9.0% | N/A | $4.8M-12.1% | $5.9M+25.2% | $5.6M+18.2% | N/A | $5.4M+20.4% |
| Operating Income | -$9.2M+66.0% | -$11.0M+49.8% | N/A | -$19.2M+3.6% | -$27.1M-69.3% | -$21.8M-44.7% | N/A | -$19.9M-2.7% |
| EBITDA | $11.8M+144.0% | -$10.9M+49.2% | N/A | -$18.9M+2.3% | -$26.8M-70.6% | -$21.5M-45.6% | N/A | -$19.4M-1.7% |
| Net Income | -$2.8M+89.7% | -$1.2M+94.5% | N/A | -$18.7M-0.5% | -$26.7M-83.2% | -$21.2M-54.7% | N/A | -$18.6M-6.2% |
| EPS (Basic) | -$0.10+94.3% | -$0.04+97.2% | $0.23+114.0% | -$1.13+8.9% | -$1.74-79.4% | -$1.41-36.9% | -$1.64-9.3% | -$1.24+22.5% |
| EPS (Diluted) | -$0.10 | -$0.04 | $0.23 | -$1.13 | -$1.74-79.4% | -$1.41-36.9% | -$1.64-9.3% | -$1.24 |
| Diluted Shares (Avg) | 29M | 29M | N/A | 17M | 15M+2.3% | 15M+12.7% | N/A | 15M |
Not reported in any period shown, so not listed: Revenue, Gross Profit, Interest Expense, Income Tax.
JSPRW Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $11.8M-74.6% | $21.2M-63.2% | $35.8M-55.2% | $57.5M-42.2% | $46.5M-59.2% | $57.6M-54.3% | $79.9M-15.8% | $99.4M-10.0% |
| Current Assets | $11.6M-73.1% | $20.3M-61.8% | $34.6M-54.3% | $54.6M-42.4% | $43.0M-60.5% | $53.2M-55.8% | $75.8M-14.8% | $94.8M-9.9% |
| Cash & Equivalents | $7.3M-81.5% | $14.1M-71.0% | $28.7M-59.9% | $50.9M-45.0% | $39.5M-63.0% | $48.8M-58.8% | $71.6M-17.6% | $92.5M-10.9% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0-100.0% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $10.4M-54.8% | $17.8M+15.8% | $31.6M+73.5% | $45.9M+191.7% | $23.0M+68.6% | $15.4M+20.6% | $18.2M+10.8% | $15.7M-3.3% |
| Current Liabilities | $7.8M-61.7% | $9.0M-27.1% | $13.2M-13.4% | $21.0M+68.9% | $20.5M+103.6% | $12.3M+38.3% | $15.2M+23.1% | $12.5M+4.6% |
| Non-Current Liabilities | $2.5M+3.2% | $8.8M+191.1% | $18.4M+516.7% | $24.9M+659.2% | $2.5M-30.6% | $3.0M-20.9% | $3.0M-26.7% | $3.3M-25.0% |
| Total Equity | $1.4M-94.0% | $3.4M-92.0% | $4.2M-93.3% | $11.6M-86.2% | $23.5M-76.6% | $42.2M-62.7% | $61.7M-21.4% | $83.7M-11.1% |
| Retained Earnings | -$320.6M-11.0% | -$317.8M-21.3% | -$316.7M-31.5% | -$307.6M-42.0% | -$288.8M-45.9% | -$262.1M-43.0% | -$240.9M-42.0% | -$216.5M-41.5% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
JSPRW Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$6.9M+55.2% | -$14.5M+36.3% | -$21.9M-3.5% | -$17.0M-21.0% | -$15.5M-32.3% | -$22.8M-45.2% | -$21.1M-28.2% | -$14.1M-17.3% |
| Depreciation & Amortization | $21.0M+6900.0% | $21K-92.5% | $290K+18.4% | $229K-54.2% | $300K0.0% | $279K-3.1% | $245K | $500K+66.7% |
| Stock-Based Compensation | N/A | $423K-76.6% | N/A | $1.4M-28.7% | $1.8M+22.6% | $1.8M+54.9% | N/A | $2.0M+43.2% |
| Investing Cash Flow | N/A | N/A | $0+100.0% | $0+100.0% | $1K+100.6% | $4K+116.0% | -$76K+67.0% | -$274K |
| Financing Cash Flow | N/A | N/A | -$340K-198.6% | $28.4M+315322.2% | N/A | N/A | $345K+227.3% | $9K-75.0% |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
JSPRW Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -195.3%-81.6pp | -34.5%+15.8pp | N/A | -161.9%-139.7pp | -113.7%-99.2pp | -50.3%-38.2pp | N/A | -22.3%-3.6pp |
| Return on Assets | -23.4%+34.1pp | -5.5%+31.3pp | N/A | -32.6%-13.9pp | -57.5%-44.7pp | -36.9%-26.0pp | N/A | -18.8%-2.9pp |
| Current Ratio | 1.48-0.6x | 2.26-2.1x | 2.62-2.4x | 2.59-5.0x | 2.10-8.7x | 4.31-9.2x | 4.98-2.2x | 7.61-1.2x |
| Debt-to-Equity | 7.35+6.4x | 5.23+4.9x | 7.62+7.3x | 3.97+3.8x | 0.98+0.8x | 0.36+0.3x | 0.30+0.1x | 0.190.0x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Where Jasper Therapeutics Inc Ranks
Frequently Asked Questions
Is Jasper Therapeutics Inc profitable?
No, Jasper Therapeutics Inc (JSPRW) reported a net income of -$76 in fiscal year 2025.
What is Jasper Therapeutics Inc's EBITDA?
Jasper Therapeutics Inc (JSPRW) had EBITDA of -$82.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Jasper Therapeutics Inc's return on equity (ROE)?
Jasper Therapeutics Inc (JSPRW) has a return on equity of 0.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Jasper Therapeutics Inc's operating cash flow?
Jasper Therapeutics Inc (JSPRW) recorded an outflow of $77.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Jasper Therapeutics Inc's total assets?
Jasper Therapeutics Inc (JSPRW) had $35.8M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Jasper Therapeutics Inc spend on research and development?
Jasper Therapeutics Inc (JSPRW) invested $63.1M in research and development during fiscal year 2025.
What is Jasper Therapeutics Inc's current ratio?
Jasper Therapeutics Inc (JSPRW) had a current ratio of 2.62 as of fiscal year 2025, which is generally considered healthy.
What is Jasper Therapeutics Inc's debt-to-equity ratio?
Jasper Therapeutics Inc (JSPRW) had a debt-to-equity ratio of 7.62 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Jasper Therapeutics Inc's return on assets (ROA)?
Jasper Therapeutics Inc (JSPRW) had a return on assets of 0.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Jasper Therapeutics Inc's Piotroski F-Score?
Jasper Therapeutics Inc (JSPRW) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Jasper Therapeutics Inc's earnings high quality?
Jasper Therapeutics Inc (JSPRW) reported a net loss of $76 while operations used $77.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.